Samantha Budd, Author at Optical Prism Magazine

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology

Posted by Samantha Budd | May 24, 2023 | Articles, News |

Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and...

Some of the best ways to grow on social media are not through social media

Posted by Samantha Budd | May 23, 2023 | Tip of the week |

THE WHY: Focusing on your social media strategy and growing your accounts can help you build brand...

IRIS, The Visual Group, a banner of the New Look Vision Group Inc., and DIAGNOS launch IRIS-ai

Posted by Samantha Budd | May 23, 2023 | Articles, News |

IRIS-ai, an artificial intelligence-powered tool for ocular disease screening, has officially been...

Linda Farrow ‘Postcards From Rio’

Posted by Samantha Budd | May 23, 2023 | Eyewear |

LINDA FARROW is delighted to announce its new Autumn Winter 2023 collection ‘Postcards from Rio’, inspired by the vibrant and buzzing city of Rio de Janeiro. The city has a unique and special way of life which champions...

CooperVision Specialty EyeCare Introduces Visavy(R) to New Markets

Posted by Samantha Budd | May 23, 2023 | Articles |

Former Specialty Lens Fitting Platform Undergoes Enhancements to Streamline Processes for Eye Care...

Author: Samantha Budd

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology

Some of the best ways to grow on social media are not through social media

IRIS, The Visual Group, a banner of the New Look Vision Group Inc., and DIAGNOS launch IRIS-ai

Linda Farrow ‘Postcards From Rio’

CooperVision Specialty EyeCare Introduces Visavy(R) to New Markets